Delta-tocotrienol Inhibits Non-small-cell Lung Cancer Cell Invasion Via the Inhibition of NF-κB, UPA Activator, and MMP-9
Overview
Affiliations
Background: Delta-tocotrienol (δT), an isomer of vitamin E, exhibits anticancer properties in different cancer types including non-small-cell lung cancer (NSCLC). Yet, anti-invasive effects of δT and its underlying cellular mechanism in NSCLC have not been fully explored. Matrix metalloproteinase 9 (MMP-9)-based cell migration and invasion are critical cellular mechanisms in cancer development. The current evidence indicates that MMP-9 is upregulated in most patients, and the inhibition of MMPs is involved in decreasing invasion and metastasis in NSCLC. Therefore, its suppression is a promising strategy for attenuating cell invasion and metastasis processes in NSCLC.
Purpose: The aim of this study was to evaluate the possibility of MMP-9 inhibition as the underlying mechanism behind the antimetastatic properties of δT on NSCLC cells.
Methods: The effects of δT on cell proliferation, migration, invasion, adhesion, and aggregation capabilities were investigated using different cell-based assays. An inhibitory effect of MMP-9 enzyme activity with δT was also identified using gel zymography. Using real-time PCR and Western blot analysis, a number of cellular proteins, regulatory genes, and miRNA involved in the Notch-1 and urokinase-type plasminogen activator (uPA)-mediated MMP-9 pathways were examined.
Results: The study found that δT inhibited cell proliferation, cell migration, invasion, aggregation, and adhesion in a concentration-dependent manner and reduced MMP-9 activities. Real-time PCR and Western blot analysis data revealed that δT increased miR-451 expressions and downregulated Notch-1-mediated nuclear factor-κB (NF-κB), which led to the repressed expression of MMP-9 and uPA proteins.
Conclusion: δT attenuated tumor invasion and metastasis by the repression of MMP-9/uPA via downregulation of Notch-1 and NF-κB pathways and upregulation of miR-451. The data suggest that δT may have potential therapeutic benefit against NSCLC metastasis.
Chiaramonte R, Sauro G, Giannandrea D, Limonta P, Casati L Antioxidants (Basel). 2025; 14(1).
PMID: 39857449 PMC: 11760857. DOI: 10.3390/antiox14010115.
Ma Y, Cui Q, Zhu W, Wang M, Zhai L, Hu W Drug Des Devel Ther. 2024; 18:1531-1546.
PMID: 38737331 PMC: 11088378. DOI: 10.2147/DDDT.S449139.
Anti-metastatic effect of taraxasterol on prostate cancer cell lines.
Movahhed M, Pazhouhi M, Esmaeili Gouvarchin Ghaleh H, Jalali Kondori B Res Pharm Sci. 2023; 18(4):439-448.
PMID: 37614618 PMC: 10443670. DOI: 10.4103/1735-5362.378090.
The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma.
Li Z, Wei J, Chen B, Wang Y, Yang S, Wu K Molecules. 2023; 28(9).
PMID: 37175113 PMC: 10180081. DOI: 10.3390/molecules28093705.
Pang K, Foong L, Ghafar N, Soelaiman I, Law J, Leong L Nutrients. 2022; 14(20).
PMID: 36296960 PMC: 9611384. DOI: 10.3390/nu14204277.